ArticleBMC veterinary research2026
Hypertrophic cardiomyopathy in cats: clinical prevalence, risk factors, and outcomes of arterial thromboembolism in a referral population in Tehran, Iran (2020-2024).
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is the most common cardiac disease in cats, yet epidemiological data from Iran are scarce. This study investigated the prevalence of HCM in a referral population of cats in Tehran, Iran, evaluated breed predisposition, characterized clinical findings, and assessed thromboembolic complications in cats referred for suspected cardiac disease.
methodsA retrospective multicenter study was conducted using medical records from seven major veterinary hospitals in Tehran between 2020 and 2024. A total of 7,013 cats evaluated for suspected cardiac disease were included. HCM was diagnosed by echocardiographic evidence of diastolic left ventricular wall thickness > 6 mm, excluding cats with documented or clinically confirmed systemic hypertension or hyperthyroidism. Clinical and diagnostic variables were extracted. Arterial thromboembolism (ATE) was diagnosed based on clinical presentation and Doppler ultrasonography. Univariate logistic regression was performed within the referral cohort to identify factors associated with HCM diagnosis, and Kaplan–Meier analysis was used to assess survival in cats with ATE.
resultsHCM was diagnosed in 638 cats, yielding a clinical prevalence of 9.1% within the referral cohort. The highest within-breed prevalence of HCM in the referral cohort was observed in Persian cats (54.8%), followed by Sphynx (46.9%) and British Shorthair (45.0%).Univariate logistic regression analysis (N = 7,013) identified adult age (OR = 5.70, p < 0.001) and high body condition score (OR = 4.05, p < 0.001) as significant predictors of HCM. ATE occurred in 36 cats and carried a poor prognosis; only three cats survived after surgical intervention. Kaplan–Meier analysis demonstrated declining survival probability in cats with arterial thromboembolism over the available follow-up period.
conclusionsHCM is a frequent and clinically significant disease among cats referred for suspected cardiac disease to veterinary hospitals in Tehran, with clear breed predisposition and association with modifiable risk factors. Early screening may facilitate earlier detection and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.